

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/063,536	
	Filing Date	May 2, 2002	
	First Named Inventor	Goddard, et al. (as amended)	
	Art Unit	1647	
		Examiner	Jegatheesan Seharaseyon
SHEET 1 OF 2		Attorney Docket No.	GNE.3230R1C24

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
JS	1	5,407,799	04-18-1995	Studier	
	2	5,530,101	06-25-1996	Queen, et al.	
	3	6,025,156	02-15-2000	Gwynn, et al.	
	4	6,124,433	09-26-2000	Falb, et al.	
	5	6,156,500	12-05-2000	Falb, Dean	
	6	6,162,604	12-19-2000	Jacob, Chaim O.	
	7	6,228,582 B1	05-08-2001	Rodier, et al.	
	8	6,395,306 B1	05-28-2002	Cui, et al.	
	9	6,414,117 B1	07-02-2002	Levinson, D. A.	
	10	6,465,185 B1	10-15-2002	Goldfine, et al.	
	11	6,498,235 B2	12-24-2002	Sheppard, et al.	
	12	6,562,343 B1	05-13-2003	Levinson, D. A.	
	13	6,645,499 B1	11-11-2003	Lal, et al.	
	14	6,730,502 B2	05-04-2004	Van Hijum, et al.	
	15	6,737,522 B2	05-18-2004	Sundick, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
JS	16	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. 403-404, 453. New York: Garland Publishing.	
JS	17	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell</i> 4th Edition, pp. 302, 363-364, 379, 435. New York: Garland Publishing.	

Examiner Signature		Date Considered	6/13/05
--------------------	--	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/063,536	
	Filing Date	May 2, 2002	
	First Named Inventor	Goddard, et al. (as amended)	
	Art Unit	1647	
(Multiple sheets used when necessary)		Examiner	Jegatheesan Seharaseyon
SHEET 2 OF 2		Attorney Docket No.	GNE.3230R1C24

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
SS	18	The 1991 Boehringer Mannheim Biochemicals Catalog, page 557, 1991.	
	19	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	20	GYGI, et al. 1999. Correlation between protein and mRNA abundance in yeast. <i>Molecular and Cellular Biology</i> , 19(3):1720-1730.	
	21	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	22	HYMAN, et al. 2002. Impact of DNA amplification on gene expression patterns in breast cancer. <i>Cancer Research</i> , 62:6240-6245.	
	23	LEWIN, B. 1994. Oncogenes: Gene expression and cancer, Chap. 39, pp. 1196-1201. <i>Genes V</i> . New York: Oxford University Press.	
	24	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	25	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	26	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	27	ØRNTØFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular & Cellular Proteomics</i> , 1:37-45.	
	28	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	29	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. <i>Pathol. Annu.</i> , 1(27):165-190.	
	30	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. <i>World Journal of Surgical Oncology</i> , 2:13.	
	31	2002-2003 Catalog & Technical Reference, New England BioLabs, Inc., p. 122.	

1544861_1:dmb
040705

Examiner Signature	<i>J. Seharaseyon</i>	Date Considered	6/13/05
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T¹ - Place a check mark in this area when an English language Translation is attached.